Published in J Neurosci on July 28, 2010
Circadian rhythms, sleep, and metabolism. J Clin Invest (2011) 2.60
Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov (2012) 2.22
Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol (2012) 2.12
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev (2012) 1.99
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab (2013) 1.90
Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev (2011) 1.85
Calorie restriction and sirtuins revisited. Genes Dev (2013) 1.79
Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab (2013) 1.74
SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell (2013) 1.71
Sirtuin 1 in lipid metabolism and obesity. Ann Med (2011) 1.65
SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice. PLoS One (2016) 1.41
Sirtuins at a glance. J Cell Sci (2011) 1.41
Resveratrol: French paradox revisited. Front Pharmacol (2012) 1.40
Effects of resveratrol and SIRT1 on PGC-1α activity and mitochondrial biogenesis: a reevaluation. PLoS Biol (2013) 1.40
Sirtuins: guardians of mammalian healthspan. Trends Genet (2014) 1.36
Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol (2013) 1.31
SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai) (2013) 1.25
Reactive oxygen species in skeletal muscle signaling. J Signal Transduct (2011) 1.23
SIRT1 in neurodevelopment and brain senescence. Neuron (2014) 1.22
Mammalian sirtuins and energy metabolism. Int J Biol Sci (2011) 1.17
Dissecting systemic control of metabolism and aging in the NAD World: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett (2011) 1.17
The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol (2011) 1.16
The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes (2011) 1.16
Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol (2011) 1.14
The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes Metab (2013) 1.10
Daytime sleepiness in obesity: mechanisms beyond obstructive sleep apnea--a review. Sleep (2012) 1.08
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain. Nat Cell Biol (2013) 1.03
SIRT1 regulation of wakefulness and senescence-like phenotype in wake neurons. J Neurosci (2011) 0.98
SIRT1 in the brain-connections with aging-associated disorders and lifespan. Front Cell Neurosci (2015) 0.93
SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice. Cell Metab (2015) 0.92
Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding. FASEB J (2011) 0.91
A nutrient-sensitive interaction between Sirt1 and HNF-1α regulates Crp expression. Aging Cell (2011) 0.91
Sirtuins: from metabolic regulation to brain aging. Front Aging Neurosci (2013) 0.90
Hypothalamic SIRT1 prevents age-associated weight gain by improving leptin sensitivity in mice. Diabetologia (2013) 0.87
Systemic regulation of mammalian ageing and longevity by brain sirtuins. Nat Commun (2014) 0.87
Sirtuins and pyridine nucleotides. Circ Res (2012) 0.86
Overexpression of SIRT1 in mouse forebrain impairs lipid/glucose metabolism and motor function. PLoS One (2011) 0.86
Metabolic actions of hypothalamic SIRT1. Trends Endocrinol Metab (2012) 0.86
The pleiotropic effect of physical exercise on mitochondrial dynamics in aging skeletal muscle. Oxid Med Cell Longev (2015) 0.85
SIRT1-mediated deacetylation of CRABPII regulates cellular retinoic acid signaling and modulates embryonic stem cell differentiation. Mol Cell (2014) 0.84
Sirtuin biology and relevance to diabetes treatment. Diabetes Manag (Lond) (2012) 0.83
Regulation of neurons in the dorsal motor nucleus of the vagus by SIRT1. Front Neurosci (2014) 0.82
Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev (2014) 0.81
The promise and perils of HDAC inhibitors in neurodegeneration. Ann Clin Transl Neurol (2014) 0.81
Senescence in adipose-derived stem cells and its implications in nerve regeneration. Neural Regen Res (2014) 0.80
Retracted Central Sirt1 regulates body weight and energy expenditure along with the POMC-derived peptide α-MSH and the processing enzyme CPE production in diet-induced obese male rats. Endocrinology (2014) 0.79
Role of the hypothalamus in mediating protective effects of dietary restriction during aging. Front Neuroendocrinol (2012) 0.79
Minireview: Central Sirt1 regulates energy balance via the melanocortin system and alternate pathways. Mol Endocrinol (2014) 0.79
Central Sirt1 regulates body weight and energy expenditure along with the POMC-derived peptide α-MSH and the processing enzyme CPE production in diet-induced obese male rats. Endocrinology (2014) 0.78
Limited role of Sirt1 in cancer protection by dietary restriction. Cell Cycle (2011) 0.78
Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra. Curr Gerontol Geriatr Res (2012) 0.78
Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. Cell Metab (2015) 0.78
Tissue Specific Expression of Cre in Rat Tyrosine Hydroxylase and Dopamine Active Transporter-Positive Neurons. PLoS One (2016) 0.75
Epigenetic alterations in the suprachiasmatic nucleus and hippocampus contribute to age-related cognitive decline. Oncotarget (2015) 0.75
Deficiency of Prdm13, a dorsomedial hypothalamus-enriched gene, mimics age-associated changes in sleep quality and adiposity. Aging Cell (2014) 0.75
The Genetic Architecture of Major Depressive Disorder in Han Chinese Women. JAMA Psychiatry (2017) 0.75
SIRT1 in the Ventromedial Hypothalamus: A Nutrient Sensor Input Into the Internal Timekeeper. Endocrinology (2015) 0.75
Insights into the role of neuronal glucokinase. Am J Physiol Endocrinol Metab (2016) 0.75
Nutrigenomics at the Interface of Aging, Lifespan, and Cancer Prevention. J Nutr (2016) 0.75
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature (2000) 20.54
Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature (2001) 14.44
The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev (1999) 14.43
Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science (2000) 12.98
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 12.66
Caloric restriction delays disease onset and mortality in rhesus monkeys. Science (2009) 9.84
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 9.84
Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A (2004) 9.25
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
The genetics of caloric restriction in Caenorhabditis elegans. Proc Natl Acad Sci U S A (1998) 7.21
The effect of retarded growth upon the length of life span and upon the ultimate body size. 1935. Nutrition (1992) 6.77
Overview of caloric restriction and ageing. Mech Ageing Dev (2005) 6.68
The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell (2008) 6.44
Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature (2003) 6.25
Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature (2007) 5.94
The meter of metabolism. Cell (2008) 5.71
Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab (2005) 5.39
The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol (2003) 5.38
The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem (2004) 5.37
Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science (2009) 5.30
Increase in activity during calorie restriction requires Sirt1. Science (2005) 4.90
The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr (1986) 4.81
Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev (2005) 4.77
Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A (2004) 4.60
Female fitness in Drosophila melanogaster: an interaction between the effect of nutrition and of encounter rate with males. Proc Biol Sci (1996) 4.44
Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science (1988) 3.95
Conserved metabolic regulatory functions of sirtuins. Cell Metab (2008) 3.86
Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron (2003) 3.61
Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science (1982) 3.59
Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet (2007) 3.59
The dorsomedial hypothalamic nucleus is critical for the expression of food-entrainable circadian rhythms. Nat Neurosci (2006) 3.29
The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods (1989) 3.15
Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci (2010) 3.05
Central control of thermogenesis in mammals. Exp Physiol (2008) 2.74
The "other" circadian system: food as a Zeitgeber. J Biol Rhythms (2002) 2.57
Supramolecular assemblies and localized regulation of voltage-gated ion channels. Physiol Rev (2009) 2.53
Circadian food-anticipatory activity: formal models and physiological mechanisms. Neurosci Biobehav Rev (1994) 2.50
BKCa-Cav channel complexes mediate rapid and localized Ca2+-activated K+ signaling. Science (2006) 2.40
Overlapping and distinct functions for a Caenorhabditis elegans SIR2 and DAF-16/FOXO. Mech Ageing Dev (2005) 2.26
Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis (2004) 2.24
Nutritional influences on aging of Fischer 344 rats: I. Physical, metabolic, and longevity characteristics. J Gerontol (1985) 2.20
Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell (2007) 2.18
The dorsomedial hypothalamus: a new player in thermoregulation. Am J Physiol Regul Integr Comp Physiol (2006) 2.10
The comparative physiology of food deprivation: from feast to famine. Annu Rev Physiol (2006) 2.02
Minireview: ghrelin and the regulation of energy balance--a hypothalamic perspective. Endocrinology (2001) 1.92
Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab (2009) 1.88
Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci (2008) 1.75
Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol Dis (2005) 1.69
The NAD World: a new systemic regulatory network for metabolism and aging--Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys (2009) 1.58
Dietary restriction benefits learning and motor performance of aged mice. J Gerontol (1987) 1.48
Reduction in rate of occurrence of age related lesions in dietary restricted laboratory mice. Growth Dev Aging (1991) 1.45
Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. J Neurosci (2004) 1.35
Hypothalamic Sirt1 regulates food intake in a rodent model system. PLoS One (2009) 1.34
Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Physiol Behav (2002) 1.32
Plasticity of circadian behavior and the suprachiasmatic nucleus following exposure to non-24-hour light cycles. J Biol Rhythms (2004) 1.20
Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med (2004) 1.13
Activation of lateral hypothalamic neurons stimulates brown adipose tissue thermogenesis. Neuroscience (2005) 1.05
The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol (2008) 1.04
SIRT1 and caloric restriction: an insight into possible trade-offs between robustness and frailty. Curr Opin Clin Nutr Metab Care (2009) 0.93
Peripheral injection of ghrelin induces Fos expression in the dorsomedial hypothalamic nucleus in rats. Brain Res (2008) 0.89
Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice. Behav Brain Res (2002) 0.87
Central regulation of food intake in ageing. J Physiol Pharmacol (2006) 0.86
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci (2003) 7.42
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol (2005) 5.80
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem (2004) 5.37
Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science (2009) 5.30
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci (2005) 4.25
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Circadian rhythms in isolated brain regions. J Neurosci (2002) 3.82
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci (2002) 3.50
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab (2011) 3.38
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Anesthesia-induced developmental neuroapoptosis. Does it happen in humans? Anesthesiology (2004) 3.22
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res (2004) 2.82
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem (2005) 2.73
A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci U S A (2009) 2.71
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab (2010) 2.63
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
The imprinted gene Magel2 regulates normal circadian output. Nat Genet (2007) 2.18
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Come together, right...now: synchronization of rhythms in a mammalian circadian clock. Neuron (2005) 2.17
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci U S A (2004) 2.11
Clock genes, oscillators, and cellular networks in the suprachiasmatic nuclei. J Biol Rhythms (2004) 2.07
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. J Clin Invest (2007) 2.03
Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron (2009) 2.03
Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol (2006) 2.03
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem (2006) 1.98
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Photic and circadian expression of luciferase in mPeriod1-luc transgenic mice invivo. Proc Natl Acad Sci U S A (2001) 1.96
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab (2012) 1.93
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem (2005) 1.91
Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron (2002) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90
Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A (2007) 1.89
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol (2002) 1.85
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. J Neurotrauma (2007) 1.79
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab (2013) 1.74
Intrinsic, nondeterministic circadian rhythm generation in identified mammalian neurons. Proc Natl Acad Sci U S A (2009) 1.70
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol (2007) 1.70
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69